Glioma Surveillance Imaging: IAG’s Thoughleadership Guide

Glioma Surveillance Imaging: IAG's Thoughleadership Guide

Glioma surveillance imaging: IAG’s Thoughleadership Guide

Revolutionizing Glioma Treatment: IAG’s Thought Leadership in Advanced Imaging

Dr. Sotirios Bisdas, IAG’s Head of Neuro-Oncology and Neurology Clinical Research, offers groundbreaking insights into the future of glioma treatment and surveillance. His expertise highlights how advanced imaging techniques can transform drug development and patient care in neuro-oncology.

Key Takeaways for Drug Developers:

  1. Personalized Treatment Regimes: Multimodality and combined MRI/PET imaging provide a framework for tailoring treatments to individual patients, particularly crucial for immunotherapy development.

  2. Precision Oncology: Advanced imaging techniques offer a pathway to more targeted and effective drug development strategies.

  3. Comprehensive Tumor Assessment: Integration of MR perfusion, diffusion, spectroscopy, and molecular imaging allows for a more nuanced understanding of tumor behavior and treatment response.

  4. Early Efficacy Evaluation: These imaging modalities enable earlier and more accurate assessment of drug efficacy, potentially reducing trial durations and costs.

  5. Enhanced Patient Selection: Improved imaging techniques can lead to more precise patient stratification for clinical trials, increasing the likelihood of successful outcomes.

Dr. Bisdas’s expertise, backed by over 130 peer-reviewed publications and involvement in international clinical studies, underscores IAG’s position at the forefront of neuro-oncology imaging research.

By leveraging IAG’s Dynamika™ platform and advanced imaging expertise, drug developers can:

  • Accelerate go/no-go decisions in clinical trials

  • Optimize patient selection and stratification

  • Enhance the accuracy of treatment response assessments

  • Potentially reduce overall development costs and timelines

IAG’s thought leadership in this field offers drug developers a unique opportunity to revolutionize their approach to glioma treatment, paving the way for more effective therapies and improved patient outcomes.

For more insights on how IAG can transform your neuro-oncology drug development process, contact imaging.experts@ia-grp.com.

News

IAG is Attending the WCO-IOF-ESCEO Congress in Rome

Meet our team at the Osteo Congress of the year!

IAG will Attend IO360 in Boston, Massachusetts, 24 – 26 Mar

IAG is sponsoring and speaking at IO360. Schedule a meeting to connect.

Dr. Olga Kubassova to Deliver Keynote Lecture at the IBD Summitt

The President of IAG is invited to the 1st International Summit of Inflammatory Bowel Disease Monitoring.

Image Analysis Group Announces Release of DYNAMIKA V7

Image Analysis Group has released DYNAMIKA V.7, the award-winning cloud platform for clinical trial imaging. DYNAMIKA V.7 has achieved the British Standards Institute (BSI) surveillance audit certification following a recent SOC II Type I compliance certification.

Events